Objective To estimate the impact of glycaemic control and time since diabetes diagnosis on care costs incurred by people with type 2 diabetes mellitus (T2DM). Research design and methods Random-effects linear regression models were run to test the impact of average glucose control (HbA1c) and time since diabetes diagnosis on total care spending in people with T2DM, adjusting for year of onset and other covariates. Two datasets were linked, Vektis (healthcare costs reimbursed by the Dutch mandatory health insurance) and Zodiac (clinical and sociodemographic data). The sample includes 22,612 observations, grouped in 5653 individuals from the Northern part of the Netherlands, covering 4 years (2008)(2009)(2010)(2011). Results A 1% point increase in HbA1c is associated with a 2.2% higher total care costs. However, when treatment modality is included, the results are modified. A 1% point increase (11 mol/mol) in HbA1c is significantly associated with 3.4% higher total care costs for individuals without glucose-lowering treatment. Being treated with insulin is significantly associated with an increase in costs of 30-38% for every additional percentage point of HbA1c, depending on the covariates included. Without controlling for year of onset, an additional year of diabetes duration relates to 2.6% higher care costs, while this is 4.9% controlling for year of onset. The effect of HbA1c and diabetes duration differs between types of costs. Conclusion HbA1c, insulin treatment and diabetes duration are the main drivers of increasing care costs. The results signal the relevance of controlling for HbA1c together with treatment modality, diabetes duration and year of diagnosis effects.
Introduction
The number of adults with diabetes has substantially increased [1, 2] , leading to a rise in diabetes-related care costs [1] , which are projected to grow even further by 30-34% by the year 2030 worldwide [3] .
Intensive glycaemic control programs have been proven to be cost-effective [4] [5] [6] , leading to cost reduction per patient with diabetes [7] . This was, however, mainly in populations with years of onset in the 1990s and may have changed for recent cohorts that were treated more intensively [4] . Some studies measuring the economic impact of glycaemic control place their focus on the long-term savings and lifetime medical expenditures [8] [9] [10] . We present these, but also analyse the short-term effect, which has not been frequently reported in the existing literature [11] [12] [13] [14] . For instance, Degli Esposti et al. [11] used data from Italian clinical and administrative registries on 21,586 people with diabetes to analyse the 2-year diabetes-related costs according to their glycaemic level. People were classified into five categories according to the proportion of target HbA1c (HbA1c ≤ 7%) values achieved available in the follow-up records: excellent (≥ 80%), 1 good (60-79%), fair (40-59%), poor (20-39%) , and very poor (< 20%). The authors found that individuals with diabetes and good glycaemic control had mean 2-year total costs 219€ higher than those with excellent HbA1c levels. Similarly, McBrien et al. [12] concluded that people with diabetes and poor glycaemic control (8 ≤ HbA1c ≤ 9%) had mean 5-year total costs 1623$ higher than those with good HbA1c levels (HbA1c ≤ 7%).
Diabetes duration is related to higher healthcare costs, one additional year with diabetes increasing annual medical expenditures by $75 [15] . Over a longer time, medical care costs might follow a U-shaped trajectory, dropping during the first years after diagnosis and then rising again [16] . Diabetes increases healthcare costs given its associated risk of developing several chronic conditions as time since diagnosis rises [15] . Moreover, glucose level control might become more difficult over time [17] , requiring multiple treatments in the long term to achieve target glucose levels. Inherently, those aforementioned analyses have to disentangle the joint effect of age and duration, as well as take into account any possible cohort effects, since treatment changes over time. Drug therapy for glycaemic control represents 18% of the total cost [4] and treatment modality modifies the mean glucose level [18] . Over the past 20 years, diabetes treatment strategies have undergone changes. Previous analyses failed to take the cohort effects into account, motivating our analysis. As far as we know, no study has been found assessing the impact of glycaemic control on diabetes care costs adjusting for diabetes duration cohort. By including diabetes onset cohort effects, we could infer whether there is any pattern by time of diabetes diagnosis in care costs and how the cohort effects impact the associations between diabetes duration and care costs, as well as between average glucose levels, treatment intensity and total costs.
Hence, this study aims to contribute to the existing literature by estimating the impact of glycaemic control on reimbursed care costs, not necessarily diabetes-related care costs, (1) adding diabetes duration and year of diabetes onset effects, which have not been jointly analyzed before, (2) additionally controlling for diabetes treatment, by exploiting the (3) panel feature of our data.
Data and methods

Data
Two datasets were linked for the purpose of our study [19] . Vektis is an organisation who manages a claims dataset with information on all medical treatments paid for by Dutch insurance companies within the mandatory insurance package, including the costs for compulsory deductibles [20] . Zodiac includes clinical data on subjects who were included in the Zwolle Outpatient Diabetes Project Integrating Available Care (ZODIAC) study, which started in 1998.
Vektis dataset
The Vektis data cover claimed healthcare cost in the Netherlands. For the current study, individual claims data from the mandatory insurance were aggregated to annual spending and into four categories, such as hospitalization and specialist medical care, drugs, general practitioners, and devices.
ZODIAC dataset
ZODIAC started as a prospective observational study examining the effect of integrated care in people with type 2 diabetes mellitus (T2DM) in Zwolle, the Netherlands. This shared care initiative expanded to nearby regions in the Netherlands in later years [21] . ZODIAC contains information routinely gathered in primary care, as well as routine laboratory measurements. Table A1 in the Online Appendix provides a detailed description of the variables used in the analysis.
For the current study, data of all patients participating from year 2008 to 2011 in ZODIAC data were linked at Vektis to the claims dataset to identify the health care spending of those patients using the unique citizen service number or unique Insurance number. 
Variables description
Dependent variable: care costs
Total care costs reimbursed to people with diabetes, but not necessarily related to diabetes, were taken for the years 2008, 2009, 2010 and 2011.
3 Table 1 shows the distribution of total care costs and the different costs components. Since the distribution of all cost items was right-skewed and to reduce heteroscedasticity [22] , we used the natural logarithm of total care costs reimbursed as our main dependent variable. There was still some right-skewness in the logarithm, but far less dramatic than with the original approach.
Secondary outcomes were the logs of costs categorized by four different categories, namely GP, hospitalization, drugs and devices cost. Remaining cost categories (i.e. obstetrics, costs abroad, etc.) were aggregated into "other costs" and not analyzed separately. All costs were inflated or deflated to 2010 euros, using the Dutch Consumer Price Index (CPI) from Statistics Netherlands. 4 
Independent variables
Glycaemic control, represented by HbA1c, is a continuous variable expressed as a percentage of glycated haemoglobin, with 5.7% as the maximum value indicating non-diabetic HbA1c levels and ≥ 6.5% in case of having diabetes [23] . HbA1c is the representation of the efforts made to reach adequate metabolic control and the underlying disease severity. Hence, glycaemic control in our analyses was adjusted by type of medication: 0, no glucose-lowering treatment; 1, oral medication and 2, insulin.
Time since diabetes diagnosis (duration), and the square of duration were included to control for its potential decreasing marginal effect. Dummy variables for 3 years of diagnosis cohorts were generated to study cohort effects by onset of diabetes, which could help to explain potential variations in care costs over time among those individuals with shared duration.
Chronic conditions were corrected for by means of Elixhauser comorbidities [24] [25] [26] , using the International Classification of Primary Care (ICPC) codes available in ZODIAC. The ICPC codes were converted to corresponding International Classification of Diseases (ICD) codes [27] . Table A1 , Online Appendix lists codes as used. Comorbidities were divided into diabetes non-related 5 and diabetesrelated 6 conditions. Dummies for every GP were added to our analysis as there might be a GP treatment effect. Additionally, we included dichotomous variables for those who are currently smoking, for gender and ethnicity (non-white); age and its quadratic form were included to control for its potential decreasing marginal effect. Finally, dummies for socioeconomic status were included. Vektis scores socioeconomic status according to postcode characteristics (average household income, type of houses in the postcode, environment characteristics, such as number of schools, institutes and any other education institution (and distance), availability of healthcare centres and other social services, etc.) with the distribution of data following a normal distribution. 3 Costs that were not included were uninsured care (i.e. informal care), as well as care from any additional insurance (treatments not or only partly covered by the mandatory package; for instance, dental care for people aged 18 years old and above, alternative medical treatments (homoeopathy), or hearing aids). 4 h t t p : / / s t a t l i n e . c b s . n l / S t a t W e b / p u b l i c a t i o n/?VW=T&DM=SLEN&PA=83131 ENG&LA=EN. 5 Diabetes non-related conditions refer to cancer, alcohol abuse, paralysis, chronic pulmonary disease, hypothyroidism, liver disease, peptic ulcer, rheumatoid arthritis, anaemia, psychosis and depression. 6 Congestive heart failure, acute myocardial infarction, peripheral vascular disease, uncomplicated hypertension, complicated hypertension, stroke, any other cerebrovascular accident, dementia, retinopathy, neuropathy, renal failure, weight loss, obesity were considered the diabetes-related comorbidities. 
Statistical analyses
Before performing statistical analyses, data were represented graphically, group by year of onset cohort. Random-effects linear regression models were applied to take into account individual variation between the 4 years included in the analysis, allowing time-invariant factors to be associated with the outcome [22] .
The baseline model with random-effects used was where log(total care cost it ) represents the logarithm form of the total care costs claimed by individual i with type 2 diabetes mellitus in year t; SE it is a vector of explanatory variables referring to age and age squared, gender, ethnicity and SES categories; HbA1c it denotes a continuous variable referring to average glucose control, in %; smoker it refers to being a current smoker. c i represents the random-effects term, which is assumed to be mean independent of the right hand side variables. u it denotes the idiosyncratic error term. Note this model ignores duration, treatment and cohort effects.
In a second regression model, treatment (oral medication or insulin) and its interaction with average glucose control were included in the regression. Diabetes duration and its square were added in a third regression model. A fourth model added the dummies for the 3 years of diabetes onset cohorts. Finally, GP dummies were added to control for any potential GP efficiency treatment.
The full model with random-effects then had the following form:
where treatment it is a vector of treatment variables referring to both dichotomous variables oral medication and insulin; HbA1c it × treatment it denotes the interaction term between HbA1c and treatment modality; diabetesdur it and diabetesdur 2 it represent the diabetes duration and diabetes duration squared. year of diagnosis i denotes a vector of 3 years of diagnosis cohort dummy variables and GP it the vector of GP identification code dummies.
(1)
Sensitivity analyses 7
To test the robustness of our results, diabetes non-related comorbidities are included in a sixth regression model and diabetes-related conditions in a seventh model.
By cost component
The full specification (model 5) was also applied to assess the relationship between the independent variables and the separate costs categories (GP costs, hospital and specialists, and drugs costs). However, devices costs showed a substantial proportion of zeros (Table 1 ) and hence a two-part model was applied [29] .
The first stage defines a dichotomous variable R indicating the regime into which observations of the dependent variable y, devices costs, falls [30] :
where y * it is a latent variable representing devices costs claimed; the vector x 1it denotes its determinants, which would be the independent variables detailed in "Independent variables"; τ is a vector of associated parameters, and it is an error term with a standard normal distribution. R it = 1 indicates that y it > 0, whereas R it = 0 is equivalent to y it = 0.
After estimating τ using Probit estimation techniques, the second stage involves a generalized linear model (GLM) with gamma distribution and log link regression of the parameters β that affect the expected value E [ y it |y it > 0] conditional on having claimed any devices costs, y it , i.e., R it = 1: where x 2it includes the determinants of the dependent variable y it . The expected value of the dependent variable y it , devices costs, consists of two parts, with the first part resulting from the first stage [3] 
) , and the second part being the conditional expectation E[y it |y it > 0] from the second stage [4] .
Results
Sample characteristics 8
Descriptive analyses for the entire sample and by average glucose control 9 are reported in Table 2 . Table A4 , Online Appendix, reports a descriptive analysis on the prevalence of Elixhauser comorbidities.
The mean total care cost incurred by people with diabetes in the whole sample is €4361, with hospitalization and drugs costs the highest cost components (€2260 and €1008, respectively). 52% of the samples are women, mean age 68.38 years. The mean diabetes duration is 7.69 years and the mean HbA1c 6.77%. 85% of the sample takes oral medication, whereas 15% uses insulin. Compared to many other T2DM studies a large proportion of elderly is included in the cohort. Table 2 suggests differences across average glucose control group. Care costs are higher for those with HbA1c above 7.5% (€4913) and HbA1c ≤ 6.5% (€4394), compared to the subjects with HbA1c between 6.5% and 7.5% (€4160). Hospitalization and drugs costs are the largest costs components across average glucose control categories, although some variances are also observed. Moreover, as expected, people with higher HbA1c's are more likely to use insulin than people within lower HbA1c's. HbA1c is higher with longer duration.
Graphical representation of the relationship between costs, average glucose control and time since diagnosis Figure 1 indicates that, when the cross-sectional feature is considered, the increase in the costs is smaller than when moving along the line of every cohort. This implies that the figure is suggestive of existing year of onset cohort effects. By ignoring year of diabetes onset effects, the costs-diabetes duration gradient would be underestimated.
Moreover, it can be observed that the biggest cohort time effect is between the cohort newly diagnosed (diabetes diagnosis in years 2007-2009) and the diabetes onset cohort between 2004 and 2006. Similar differences between year of onset cohorts were observed for all subcategories of costs, except for GP costs. The year of onset effects were quite small for drugs costs ( Figure A1 , Online Appendix).
Similarly, Fig. 2 shows that average glucose control deteriorates with diabetes duration. The differences between cohorts seem small in this case, indicating minor cohort effects. Table 3 reports the results 10 obtained from the random-effects linear regression model applied to the overall sample. Without correction for onset cohort, treatment and duration, the first regression model shows that a 1% point increase in HbA1c is significantly associated with higher total care costs by 2.22.%. Moreover, an additional year of age is related to greater total care costs by 2.11%. 11 Age squared is not significant individually, but age and age squared are jointly significant.
Regression results
When the diabetes treatment dummies and the interactions between diabetes treatment and average glucose control are introduced (model 2), a significant association between treatment and average glucose control and care costs is shown, decreasing the significance of HbA1c alone. An additional year of age is associated with significantly higher total care costs by 2.04%, on average. A 1% point rise in HbA1c is related to higher total care costs by 3.42% if the individual is not being treated with insulin or with oral medication. The effect of HbA1c in people treated with oral medication or insulin on total care costs is not significant. Taking oral glucose-lowering medication is not related to care costs. In contrast, treatment with insulin is significantly associated with an increase in costs of 37.83%.
12 Fig. 1 Mean logarithm of total care costs by diabetes duration and cohort Fig. 2 Glycaemic control levels by year at onset cohorts 11 The average marginal effect and p value of age (and diabetes duration) were calculated using the command lincom from Stata 14.0, using the regression coefficients for age and age squared (diabetes duration and its square) as well as the mean age (diabetes duration) for the overall sample. For example, the average marginal effect of an additional year of age is calculated as follows: coefficient of age + 2 × coefficient of age 2 × (mean age) = 0.0174262 + 2 × 0.000026 6 × 68.38 = 0.0210593 (z value = 21.68, p value = 0.000). 12 The coefficient and p value of variables part of interactions in the regression model were obtained using the command lincom from Stata 14.0. For example, the coefficient of insulin is calculated as follows: coefficient of insulin alone + coefficient of the interaction HbA1c # insulin × mean HbA1c = 0.658 − 0.0498 × 6.77. Once we obtained this coefficient and given the logarithmic form of our regression model, we calculated the insulin coefficient as follows: (e coef − 1) × 100 = (e 0.3208 − 1) × 100 = 37.83. . The second part of the calculation was followed for every dummy variable included in the main analysis (treatment modalities and diabetes onset cohorts) and in the sensitivity analysis (Elixhauser comorbidities). 10 A coefficient will be considered statistically significant if it is significant, at least, at 95% confidence level (p value = 0.05). Adding diabetes duration and its square (model 3) leads to HbA1c level being no longer significant individually, or depending on treatment. The average marginal effect of age is still related to higher costs, but it drops to 1.71%. Age squared individually is not significant. Being treated with insulin is significantly associated with an increase in total costs of 30.21% for every percentage point rise in HbA1c levels. Each additional year of time since diabetes diagnosis is significantly related to higher care costs, which are augmented by 2.55%, on average, although the negative sign of the square of diabetes duration shows that such effect will be decreasing at some point.
When cohort effects are introduced (model 4), this result in non-significance for HbA1c and age squared as in model 3. An additional year of age is significantly related to higher total costs by 1.64% points. Being treated with insulin is significantly associated with 33.68% greater costs for each 1% point increase in HbA1c. Each additional year of time since diabetes diagnosis is related to an increase of care costs of 4.88%, with a negative sign of the square of diabetes duration. The year of onset dummies are significant. Compared to individuals who have been recently diagnosed with diabetes, those whose diabetes onset has occurred between 2004 and 2006 are associated with lower care costs of 17.00%. This difference increases up to 102.59% for the cohort being diagnosed before the year 1989. Figure 3 shows that the time point at which care costs start decreasing in model 4 is around 35 years of diabetes duration, which is later than in model 3 with a turning point around 25 years of diabetes duration. The figure would be suggestive of a "healthy survivor" effect. Having consistently little health care claims during 25-35 years since diagnosis and hence probably staying uncomplicated might imply lower likelihood of developing complications.
Similar results are found in model 5, with GP dummies added. These are jointly significant. Age squared is not significant, neither is HbA1c. An additional year of age is significantly related to higher total costs, by 1.64%. Insulin treatment is significantly related to 34.06% higher costs for every 1% point rise in HbA1c. Every additional year of time since diabetes diagnosis is associated with 4.63% larger costs, with a decreasing difference. Dummies for year of onset cohorts are significant.
Sensitivity analysis
In case of the regression model with the non-diabetes-related Elixhauser comorbidities (Table A5 , Online Appendix), age individually, being treated with insulin, duration since diabetes diagnosis, and year of onset cohorts remain significant determinants of higher care costs. Age squared is not significant. HbA1c, regardless of diabetes treatment, is not significantly associated with care costs. Within the list of comorbidities, suffering from cancer, anaemia and depression have the strongest association with total care costs, rising by 87.57%, 19.72% and 16.30%, respectively.
In the last regression model where diabetes-related complications are included, age squared is not significant, nor is HbA1c, regardless of diabetes treatment. An additional year of age is related to higher total costs by 0.69%. Being treated with insulin is significantly associated with 34.81% greater costs for every percentage point increase in HbA1c. Each additional year of time since diabetes diagnosis is associated with 5.83% higher costs. Dummies for year of onset cohorts are significantly related to care costs. With respect to the chronic conditions newly considered, suffering from weight loss, peripheral vascular disease and congestive heart failure show the strongest association with health care costs, rising by 75.59, 42.62 and 42.48% points in the presence of these comorbidities, respectively. GP costs For GP costs, interaction terms of treatment and HbA1c are significant, as are age variables.
By cost component
A 1% point increase in HbA1c is significantly associated with 3.48% higher GP costs for individuals without diabetes medication. If the person takes oral medication, a 1% point rise in HbA1c is significantly related to lower GP costs. For individuals using insulin, a 1% point increase in HbA1c is associated with 0.90% higher GP costs. When looking at the effect of diabetes treatments, taking oral medication is significantly related to lower GP costs, which decrease by 4.63% for each additional percentage point of HbA1c. Being treated with insulin is associated with 7.78% higher GP costs for every percentage point of HbA1c. Each additional year of Table 4 Results from the random-effects linear regression model on the different costs components Clustered standard errors at the individual level in parentheses. ***p < 0.01, **p < 0.05, *p < 0.1 Reference categories: men, Caucasian ethnicity, high SES, no current smokers, no medication, year of diabetes onset [2007] [2008] [2009] Model 5 includes socioeconomic characteristics (gender, age, ethnicity, and socioeconomic status), being a current smoker, glycaemic level, the interaction between glycaemic level and type of medication (oral medication or insulin), diabetes duration and its quadratic form, the year of diabetes onset groups and the dummies for the general practitioners (GPs) Devices costs Higher HbA1c, both types of diabetes treatment (oral medication and insulin), diabetes duration and diabetes duration squared are positively and significantly associated with the probability of incurring any devices costs. Moreover, age significantly reduces the probability of having devices costs. Also, 3-year onset categories are jointly significant and have a negative effect on the probability of claiming devices costs. The GLM results from the second part two-part model show that HbA1c is never related to the level of devices costs. Being treated with insulin is significantly associated with 40.48% higher devices costs for 1% point increases in HbA1c. Diabetes duration and year of onset cohort are not determinants of devices costs.
Discussion
In this paper, we aimed to estimate the impact of average glucose control on total care costs incurred by people with diabetes, but not exclusively diabetes-related costs, in adult people, additionally controlling for year of onset cohort effects. We used claims data for around 5600 Dutch people with diabetes who had complete data for the time period from the year 2008 to 2011. Our results show that reimbursed healthcare costs for these persons depended mainly on level of glycaemic control, type of treatment (oral medication or insulin) and diabetes duration. Our results underline the importance to control for year of onset.
The graphical representation of the relationship between total care costs and time since diabetes diagnosis seem to suggest existing year of onset cohort effects. By ignoring year of diabetes onset effects, the costs-diabetes duration gradient would be underestimated. Furthermore, it could be interpreted that, next to the cohort effect, the diabetes duration-time effect is also large. On the other hand, minor cohort effects for average glucose control levels were also found graphically. Vertical differences in average glucose control by year of diabetes diagnosis cohort at start of each cohort observation period might also reflect the different need for treatment intensification when diabetes duration increases.
The descriptive results also indicate that care costs incurred by people with diabetes type 2 differ by HbA1c level, being the proxy of average glucose control. 4-year mean total care costs are €520 higher in people with HbA1c above 7.5% compared to people with HbA1c below 6.5%, confirming previous results [11 -13, 32] . However, the regression results show that a 1% point increase in HbA1c is associated with 2.22% higher total care costs in the crude model. In addition, our results show that the impact of average glucose control on care costs is mediated by the treatment modality (in our case, oral medication or insulin). When diabetes treatments are included in the analysis, insulin use is significantly related to higher total care costs, with 30.21-37.83%, depending on the covariates included, for every percentage point increase in HbA1c. In primary care in The Netherlands, mean HbA1c in people on oral medication is 6.8%, and on insulin is 7.4% [33] . Therefore, treatment intensity is one of the factors needed to be considered in this analysis. Moreover, care costs are higher when using insulin [19, 34] , which has been confirmed by our findings. They also vary with type of insulin and regime [35, 36] , which was not available in our data.
With respect to the effect of diabetes duration, we have found that an additional year of diabetes duration is associated with higher care costs by 4.88% when year of onset categories are included. Comparing models 3 and 4 highlights the relevance of correcting for year of onset cohort effects, as not doing so would lead to biased diabetes duration estimates. Moreover, findings suggest that there is a strong association between diabetes duration and total costs. McBrien et al. [12] also looked at the impact of diabetes duration on healthcare spending. They show that care costs in people with diabetes increase with time since diagnosis, as we do, but we found moreover that the costs increase will be reversed at some point (Fig. 3) . Trogdon and Hylands [15] showed that annual medical expenditures increase at a decreasing rate with diabetes duration, which would be confirmed by our results.
The influence of average glucose control, diabetes treatment modality and diabetes duration was maintained across costs components, with some minor exceptions. In contrast to total costs, HbA1c has significant associations with some cost categories, especially with drug costs [19] and GP costs. Insulin treatment has an association to all cost categories and especially to devices and hospital and specialist costs [34] .
Some limitations should also be mentioned. First, the analyses were performed based on the population from the North of The Netherlands. Although the generalizability of the results to other country areas might be limited, we expect that the relative differences in costs would be maintained. Second, it would have been good to have a longer period of data and a greater number of complete cases to observe the same individuals for more time. Only having 4-year data might not be enough to fully disentangle the diabetes duration effect from the year of onset effect. The reimbursement and claims data allow us to assess the association between care costs and diabetes, but not to establish causality. Moreover, using ICPC codes to correct for comorbidities might be under-reporting the prevalence and, thus, the relevance of the association between comorbidities and care costs. For example, the prevalence of obesity in our data is 0.7%, whereas estimates from the World Health Organization for 2008 showed that obesity prevalence among Dutch adults was 18.8% [37] . The selection of complete cases could be a limitation of the analysis, as it could lead to selection bias by considering only the "healthy survivors" and those with complete information on all covariates. However, when looking at the summary statistics table for the original sample (Table A3 , Online Appendix), there are no big differences with respect to the final sample according to the selection criteria.
Our findings lead to several contributions to the existing literature. We not only looked at the impact of glycaemic control on care costs incurred by people with diabetes, but we also corrected for treatment modality and for diabetes duration and year of onset effects, which has not been previously done. Excluding these factors could lead to an overestimation of the influence of other variables. Our results showed that insulin treatment modality was associated with higher care costs, regardless of introducing insulin alone in the model or together with average glucose control, while HbA1c was not in all models significantly associated with total costs. This could have implications for the pharmaceutical industry when developing treatment for older people with diabetes as, instead of placing the focus largely on the management of the chronic conditions, the scope could change to average glucose control and treatment modality, which can be individually modified according to a variety of factors such as frailty. The effect of diabetes duration and year of onset cohort also points to the relevance of diabetes treatment, as people with a longer diabetes duration might be in need for different and more costly treatment. Our results suggest that if a good management of average glucose control could be implemented for a whole population, the impact of diabetes duration, which is not modifiable, and the risk of developing associated complications could be reduced. Finally, another strength of our data is that using claims data reduces biases which can be derived from other data sources, such as self-reported data [38, 39] . The available data allowed us to have access to laboratory, clinical and costs registries data, providing researchers and policymakers with reliable estimations on reimbursed care costs per patient.
In conclusion, this study underlines the need to be aware of treatment interaction and cohort of onset effects in chronic diseases like diabetes with treatment changing over time. Without suitable correction, effects of HbA1c could be overestimated. Proper correction for the role of cohort of onset and treatment will also be relevant for other chronic conditions.
